Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer

Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer

Background: The RAS/RAF/MEK/ERK signalling pathway has a pivotal role in cancer proliferation and modulating treatment response. Selumetinib inhibits MEK and enhances effects of radiotherapy in preclinical studies. Patients and methods: Single-arm, single-centre, open-label phase I trial. Patients w...

Full description

Bibliographic Details
Main Authors: K. Haslett, P. Koh, A. Hudson, W.D. Ryder, S. Falk, D. Mullan, B. Taylor, R. Califano, F. Blackhall, C. Faivre-Finn
Format: Article
Language:English
Published: Elsevier 2021-05-01
Series:Clinical and Translational Radiation Oncology
Subjects:
NSCLC
Selumetinib
Thoracic radiotherapy
MEK inhibitor
Lung cancer
Phase I
Online Access:http://www.sciencedirect.com/science/article/pii/S2405630821000239

Internet

http://www.sciencedirect.com/science/article/pii/S2405630821000239

Similar Items